Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-14
DOI
https://doi.org/10.64898/2026.11.13.762685
Primary Topic
Immunotherapy and Immune Responses
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Changhao He, Wenqi Shen, Keelan Z. Guiley, Kevan M. Shokat et al.
bioRxiv (Cold Spring Harbor Laboratory)
Immunotherapy and Immune Responses
preprint

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Changhao He, Wenqi Shen, Keelan Z. Guiley, Kevan M. Shokat, Vishal D Lashkari, Ziyang Zhang, Peter M. Bruno, Julia Hernandez
preprint en

Abstract

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

bioRxiv (Cold Spring Harbor Laboratory)
Howard Hughes Medical Institute (US), University of California, San Francisco (US), Parker Institute for Cancer Immunotherapy (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), University of California, Berkeley (US)
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Discovery of molecular glues for modulating MHC presentation of cancer neoantigens — Changhao He, Wenqi Shen, et al. · bioRxiv (Cold Spring Harbor Laboratory) (2026) | TGRS Research Map | TGRS